Prevenar Special Use-result Surveillance (Multi-center, Prospective Observational Safety Surveillance for Prevenar in Japan).
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 19 Jan 2016 Primary endpoint amended, So trial focus changed to adverse reactions as reported by ClinicalTrials.gov.
- 23 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Aug 2013 Planned End Date changed from 1 Jun 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.